Drug-induced cytolytic syndrome in pregnancy: clinical and biochemical diagnostic criteria

Abstract

The aim of the study was evaluation of clinical and laboratory manifestations of drug-induced cytolytic syndrome in pregnancy. In the research group included 62 pregnant women with drug-induced liver injury (DILI) in the first trimester of pregnancy. These pregnant women received hormone therapy at the planning stage and/or during pregnancy for the prevention and treatment of miscarriage and had clinical and biochemical manifestations of cytolytic syndrome. Pregnancy after IVF and ovulation induction was in 60.8% of cases. Hormone therapy for pregnant patients received long-term, 85% of pregnant women used estrogen and progestin drugs. DILI during pregnancy characterized by low-symptom or asymptomatic clinical manifestations. DILI manifested cytolytic biochemical syndrome, in which there is isolated increase of transaminase levels, in some cases accompanied by increased level of gamma glutamyl transpeptidase, liver glutamate dehydrogenase and decreased total protein levels, in the first place due to the albumin fraction.

Keywords

drug-induced liver disease / drugs / pregnancy / diagnostics / biochemical parameters

References

[1] 1.Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38:33-8. doi: 10.1016/j.dld.2005.06.004.

[2] 2.Wilkes RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6:904-96. doi: 10.1038/nrd2423.

[3] 3.Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924-34. doi: 10.1053/j.gastro.2008.09.011.

[4] 4.William M, Lee MD. Drug-Induced Hepatotoxicity. N Engl J Med. 2003;349:474-85. doi: 10.1056/NEJMra021844.

[5] 5.Галимова С.Ф. Лекарственные поражения печени (часть 1-я) // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2012. – № 3. – С. 38–48. [Galimova SF. Drug-induced liver injuries (part 1). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2012;(3):38-48. (In Russ.)]

[6] 6.Feghali MN, Mattison D.R. Clinical therapeutics in pregnancy. J Biomed Biotechno. 2011:783528. doi: 10.1155/2011/783528.

[7] 7.Еремина Е.Ю. Лекарственный гепатит у беременных // Врач. – 2015. – № 8. – С. 11–13. [Eremina EJu. Lekarstvennyj gepatit u beremennyh. Vrach. 2015;(8):11-3. (In Russ.)]

[8] 8.Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398-407 doi: 10.1016/j.ajog.2004.04.025.

[9] 9.Стриженок Е.А., Гудков И.В., Страчунский Л.С. Применение лекарственных средств при беременности: результаты многоцентрового фармакоэпидемиологического исследования // Клин. микробиология антимикр. химиотер. – 2007. – Т. 9. – № 2. – С. 162–175. [Strizhenok EA, Gudkov IV, Strachunskij LS. Primenenie lekarstvennyh sredstv pri beremennosti: rezul’taty mnogocentrovogo farmakojepidemiologicheskogo issledovanija. Klin mikrobiologija antimikr himioter. 2007;9(2):162-75. (In Russ.)]

[10] 10.Mitchell AA, Gilboa SM, Werler MM, et al. Medication Use Pregnancy, With Particular Focus On Prescription Drugs: 1976–2008. Am J Obstet Gynecol. 2011;205(1):51-8. doi: 10.1016/j.ajog.2011.02.029.

[11] 11.Иванников И.О., Сюткин В.Е. Общая гепатология. – М.: Медпрактика-М, 2003. – 160 с. [Ivannikov IO, Sjutkin VE. Obshhaja gepatologija. Moscow: Medpraktika-M; 2003. (In Russ.)]

[12] 12.Hay JE. Liver disease in pregnancy. Hepatology. 2008;47:1067-76. doi: 10.1002/hep.22130.

[13] 13.Kopylov U, Avidan B, Papageorgiou N, et al. Idiopathic liver function test abnormality in pregnancy is associated with assisted reproduction techniques. Fertil Steril. 2013;99:377-81. doi: 10.1016/j.fertnstert.2012.09.015.

[14] 14.Успенская Ю.Б., Кузнецова И.В., Гончаренко Н.В., Суханова Г.А. Функциональное нарушение печени в первой половине беременности // Врач. – 2013. – № 12. – С. 70–73 [Uspenskaja JB, Kuznecova IV, Goncharenko NV, Suhanova GA. Funkcional’noe narushenie pecheni v pervoj polovine beremennosti. Vrach. 2013;(12):70-73. (In Russ.)]

[15] 15.Fábregues F, Balasch J, Ginès P. Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. Am J Gastroenterol. 1999;94:994-9. doi: 10.1111/j.1572-0241.1999.01002.x.

[16] 16.Chen CD, Wu MY, Chen HF, et al. Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Hum Reprod. 2000;15:66-71. doi: 10.1093/humrep/15.5.1037.

[17] 17.Toyoda Y, Endo S, Tsuneyama K, et al. Mechanism of exacerbative effect of progesterone on drug-induced liver injury. Toxicol Sci. 2012;126:16-27. doi: 10.1093/toxsci/kfr326.

[18] 18.Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet Gynecol. 2004;103:551-63. doi: 10.1097/01.AOG.0000114989.84822.51.

[19] 19.Carbone IF, Cruz JJ, Sarquis R, et al. Assisted conception and placental perfusion assessed by uterine artery Doppler at 11–13 weeks’ gestation. Hum Reprod. 2011;26:1659-64. doi: 10.1093/humrep/der117.

[20] 20.Mei-Dan E, Wiznitzer A, Sergienko R, et al. Prediction of preeclampsia: liver function tests during the first 20 gestational weeks. J Matern Fetal Neonatal Med. 2013;26(3):250-3. doi: 10.3109/14767058.2012.733771.

RIGHTS & PERMISSIONS

Borisova I.V.